Physician profile
Simone L Fish
NPI 1932542230
$2,679.36
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $38.48 · 2021: $525 · 2022: $439 · 2023: $808 · 2024: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.20 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $283.71 | 2019-2024 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $233.38 | 2021-2024 | Breztri, Farxiga |
| Abbott Laboratories | $197.57 | 2023-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.43 | 2021-2023 | Tradjenta, Jardiance |
| Pfizer INC. | $116.99 | 2019-2024 | |
| Amgen INC. | $88.33 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $85.82 | 2019-2021 | |
| Dexcom, INC. | $59.62 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $56.41 | 2019-2023 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $54.61 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $54.56 | 2019-2024 | Rotateq, Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $51.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.19 | 2019-2023 | |
| Exact Sciences Corporation | $36.77 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.29 | 2021 | |
| Organon LLC | $19.95 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.51 | 2022 | |
| Phadia US INC. | $15.36 | 2021 | |
| Dynavax Technologies Corporation | $14.91 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2023 | |
| Fortovia Therapeutics, INC. | $13.83 | 2019 | |
| Bioventus LLC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.